Drugs / HTIG
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05625477 Comparator | Apr → May 2022 | tetanus | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HTIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05625477 ↗ |
| Modality | Protein / enzyme biologic | “human tetanus immunoglobulin (HTIG)” NCT05625477 ↗ |
| Route | Intramuscular | “Single dose of HTIG administered by intramuscular injection” NCT05625477 ↗ |